Gunlusoy Bülent, Ceylan Yasin, Degirmenci Tansu, Kozacioglu Zafer, Yonguc Tarık, Bozkurt Halil, Aydogdu Ozgü, Sen Volkan
Izmir Bozyaka Training and Research Hospital, Urology Clinic, Turkey.
Can Urol Assoc J. 2015 Sep-Oct;9(9-10):E727-30. doi: 10.5489/cuaj.3049. Epub 2015 Oct 13.
The aim of the study is to reveal pathologic characteristics and clinical behaviour of patients 40 years old or younger diagnosed with and treated for urothelial bladder carcinoma.
We retrospectively analyzed the clinical and pathologic data of 91 patients, initially diagnosed and treated at our institution from May 1996 to December 2014. Cancer recurrence was defined as new occurrence of bladder cancer at the same or different sites of the bladder. Cancer progression was defined as an increase in stage or grade in any of the recurrences.
The mean age was 33.8 (range: 17-40) years. The pathological examination after transurethral resection revealed 83 (91.2%) patients with non-muscle invasive urothelial bladder cancer, and 8 (8.8%) patients with muscle invasive urothelial bladder cancer. According to the distribution of grade, there were 75, 4 and 12 patients with grade 1, grade 2 and grade 3 diseases, respectively. Initial cancer staging was: pTa with 40 patients (43.9%), pT1 with 43 patients (47.2%), pT2 with 7 patients (7.6%), and pT3 with 1 patient (1.2%). While 17 (18.6%) patients recurred in the follow-up, 10 (10.9%) patients had progression. There were no differences in recurrence and progression rates in the Ta and T1 stages between groups (p = 0.233, p = 0.511, respectively).
The risk of progression increased as the number of relapses increased. The clinical behaviour of high-stage and high-grade disease in younger patients is similar to the older group.
本研究旨在揭示40岁及以下经诊断和治疗的膀胱尿路上皮癌患者的病理特征和临床行为。
我们回顾性分析了1996年5月至2014年12月在我院首次诊断和治疗的91例患者的临床和病理数据。癌症复发定义为膀胱同一或不同部位出现新的膀胱癌。癌症进展定义为任何一次复发中分期或分级增加。
平均年龄为33.8岁（范围：17 - 40岁）。经尿道切除术后的病理检查显示，83例（91.2%）患者为非肌层浸润性膀胱尿路上皮癌，8例（8.8%）患者为肌层浸润性膀胱尿路上皮癌。根据分级分布，分别有75例、4例和12例患者为1级、2级和3级疾病。初始癌症分期为：pTa期40例（43.9%），pT1期43例（47.2%），pT2期7例（7.6%），pT3期1例（1.2%）。随访期间，17例（18.6%）患者复发，10例（10.9%）患者病情进展。Ta期和T1期组间复发率和进展率无差异（p分别为0.233和0.511）。
随着复发次数的增加，进展风险增加。年轻患者中高分期和高分级疾病的临床行为与老年组相似。
